Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study

Clicks: 20
ID: 325157
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #168 of 412 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 412 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Vitiligo affects 0·5-2% of the global population and carries a substantial psychosocial burden. Topical ruxolitinib 1·5% cream is approved for non-segmental vitiligo based on phase-3 trial data, but real-world evidence across heterogeneous populations remains limited. OBJECTIVES: To evaluate the real-world effectiveness, safety, and patient-reported outcomes of topical ruxolitinib across 34 Italian dermatology centres, and to identify possible clinical predictors of treatment response. METHODS: Multicentre retrospective cohort study (July 2024-October 2025). Patients (≥12 years) with non-segmental vitiligo received ruxolitinib 1·5% cream twice daily. Primary outcomes were F-VASI75 and F-VASI90 at 24 and 52 weeks. Secondary outcomes were VNS, DLQI, VitiQoL, GAD-7, and PHQ-9. RESULTS: 860 patients (mean age 47 years; 58% female; disease duration 13·5 years; 84% previously treated) completed 24-week assessment; 229 (26·6%) had reached 52 weeks at the time of data lock. F-VASI75 was achieved by 18·5% at 24 weeks, increasing to 38·4% at 52 weeks; F-VASI90 rose from 5·7% to 25·8%. In multivariable logistic regression, summer treatment initiation (adjusted OR 6·7, 95% CI 2·7-16·8) and Koebner phenomenon (adjusted OR 1·6, 95% CI 1·04-2·66) were independent predictors of F-VASI75 at 24 weeks. At baseline, 37% of patients had moderate-to-severe anxiety (GAD-7 ≥10); this fell to 11% at 24 weeks and 2% at 52 weeks. VitiQoL, DLQI, and PHQ-9 improved at all timepoints. Adverse events were mild in 98·9%; treatment discontinuation rate was 1·5%. CONCLUSIONS: In a large real-world population considerably more heterogeneous than registration trial cohorts, topical ruxolitinib showed progressive repigmentation through 52 weeks with excellent tolerability. Summer initiation and Koebner phenomenon independently predicted early response, findings that may inform patient counselling and the design of prospective studies. The parallel sustained reduction in anxiety and depression argues for standardised mental health assessment as a routine component of vitiligo care.
Reference Key
openalex_W7203614220 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Angelo V Marzano, Alessandra Narcisi, Gianluca Tavoletti, Luisa C Rossi, Maurizio Romagnuolo, Matteo Bianco, Paolo Amerio, Edvige Morea, Eugenio Provenzano, Franco Rongioletti, Stefania Guida, Lorenzo Maria Pinto, Alessandra D'Amore, Maria-Concetta Fargnoli, Alessia Pacifico, Paolo Iacovelli, Pietro Rubegni, Emanuele Trovato, Marco Romanelli, Alessandra Michelucci, Giuseppe Micali, Maria L Musumeci, Aldo Lajos Di Marco, Maddalena Napolitano, Luigi Coronella, Caterina Foti, Alessandro Borghi, Lucrezia Pacetti, Serena Giacalone, Cristina Beatrice Spigariolo, Gianluca Nazzaro, Simone Ribero, Luca Mastorino, Anna Belloni Fortina, Alvise Sernicola, Oriana Simonetti, M. Matteucci, Eustachio Nettis, Luca Stingeni, Giovanni Pellacani, Annunziata Dattola, Iris Zalaudek, Raffaele D Caposiena Caro, Emiliano Antiga, Maria Efenesia Baffa, Maria Esposito, Manfredo Bruni, Paolo Sena, Pamela Vezzoli, Lorenzo Rocca, Emanuele Cozzani, Giulia Gasparini, Niccolò Capurro, Paola Savoia, Piergiacomo Calzavara‐Pinton, Mariachiara Arisi, Tomasini Carlo, Andrea Michelerio, Stefania Barruscotti, Mauro Picardo, Alessia Paganelli, Piergiorgio Malagoli, Alessandro Pileri, Roberta Giuffrida, Santo R Mercuri, Vittoria Giulia Bianchi, Giuseppe Argenziano, Elisabetta Fulgione, Giampiero Girolomoni, Martina Maurelli, Antonio Costanzo, Alessandra Cartocci, Ketty Peris, Silvia Alberti Violetti
Are you one of these authors? Claim your profile
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag342
URL
https://doi.org/10.1093/bjd/ljag342
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.